Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Covishield vaccination was associated with cutaneous adverse effects, notably telogen effluvium and urticaria, among recipients at a hospital in northern India.

In this study, 2% of healthcare workers vaccinated with Covaxin or Covishield reported new skin reactions, with a slightly higher incidence following Covaxin; significant differences were observed among paramedical staff.

This review discusses the development and rapid approval of COVID-19 vaccines and notes the observation of autoimmune disorders, such as alopecia areata, following vaccination; it provides no new clinical results.

This study reported a series of mild to moderate cutaneous adverse drug reactions following COVID-19 vaccination, predominantly after Covishield, with only one requiring hospitalization.

In this study, 19.6% of COVID-19 vaccine recipients reported post-vaccination mucocutaneous effects, mostly mild and self-limiting; the reactions were similarly frequent for Covishield and Covaxin.

This study found that multicomponent microarray patches for SARS-CoV-2 vaccination produced stronger immune responses and fewer side effects in mice compared to traditional intramuscular injection.

This report describes a rare case of pityriasis rosea-like eruption in a 52-year-old Thai woman following Oxford/AstraZeneca COVID-19 vaccination, emphasizing the condition does not preclude further vaccinations.

This study reported that 57% of healthcare workers experienced persistent post-COVID-19 complications, with common symptoms including hair loss, easy fatigability, mood swings, and anxiety.

This study observed that sera from Covaxin-vaccinated individuals showed reduced neutralization ability against the Omicron variant compared to B.1, Beta, and Delta variants, with breakthrough infections boosting immune response more effectively than vaccination alone.

This case report describes a drug-related skin eruption following AstraZeneca-Oxford vaccination, which resolved after treatment with oral prednisolone.

In this study, researchers observed temporary skin reactions at BCG vaccination sites following the Pfizer-BioNTech COVID-19 mRNA vaccine in five patients, suggesting underreported occurrences.

This study observed that dermatological patients using certain immunosuppressants, like azathioprine and high-dose prednisolone, had a reduced humoral immune response to the Sinovac-CoronaVac COVID-19 vaccine compared to those without such treatments.

This report describes two cases where a viral vector COVID-19 vaccine was associated with the recurrence of cutaneous lymphoma conditions that had been in remission.

This case report describes a 6-year-old girl who developed MIS-C following COVID-19 vaccination, raising questions about the vaccine's potential role in its pathogenesis for children aged 5 to 11.

Covid-19 vaccination during pregnancy is safe for mothers and babies.

This study observed a variety of skin conditions related to COVID-19 and its vaccines in a Brazilian setting, classifying them into five categories, including peri-infectious reactions and vaccine-related adverse effects, to aid physicians managing similar cases.

This study found that BCG injection in COVID-19 convalescent adults reduced long COVID symptoms like hearing and cognitive issues but also led to increased hair loss in women at six months.

This article discusses the potential of intralesional cidofovir as a treatment for SCC and reports no systemic toxicity, but highlights surgical excision as the most reliable curative option.

This study reviewed existing literature on chloroquine and hydroxychloroquine's safety and efficacy in COVID-19 management, finding mixed clinical evidence and highlighting the need for more rigorous trials to determine their potential role in treatment.

This article discusses topical and intralesional cidofovir use for SCC and suggests a successful outcome in one case, with no systemic toxicity observed so far.

This review discusses various skin reactions after SARS-CoV-2 infection and COVID-19 vaccination, noting a higher incidence with mRNA vaccines than adenovirus vector vaccines, and reports no new clinical results.

This study used a Lebanese national registry to document dermatologic symptoms related to COVID-19 and its vaccines, noting that urticaria and telogen effluvium were common during infection, while urticaria and herpes zoster were notable post-vaccination.

This study highlights that the ACIP strongly recommends COVID-19 vaccination and booster doses for pregnant women, those breastfeeding, or trying to conceive, due to the safety of non-live vaccines in these groups and the protection they also offer to infants.

This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.

This case study describes a 53-year-old woman who developed severe muscle weakness, myalgia, and alopecia after receiving the Pfizer SARS-CoV-2 vaccine, with partial hair regrowth observed after six months.

This study found that alkaloids isolated from Cucumis metuliferus fruit pulp demonstrated antiviral activity against IBDV in chicken embryo fibroblast cells and NDV in 10-day-old embryonated chicken eggs, while being non-cytotoxic.

This study suggests that a third Covid-19 vaccine dose is necessary to maintain protection, especially among immune-compromised individuals and those with comorbidities, emphasizing the urgent need for vaccine access in less developed regions.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

This research highlights major advancements in vaccinology, such as mRNA vaccines and nanoparticle delivery systems, enhancing vaccine efficacy and paving the way for novel vaccine development against infectious and non-infectious diseases like cancer, with implications for improved global health outcomes.